Clinical Trial Update: Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial evaluating perioperative hepatocellular carcinoma treatment with a combination of camrelizumab, apatinib, and transarterial che…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Hepatocellular Carcinoma, Immunotherapy | Phase 3 | Status: RECRUITING